24-hydroxycholesterol has been researched along with Orphan Diseases in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Austin, CP; Berry-Kravis, E; Bianconi, S; Brewer, CC; Davidson, CD; Farhat, NY; Jiang, X; Kao, M; Keener, LA; King, KA; Machielse, BN; McKew, JC; Ory, DS; Ottinger, EA; Pavan, WJ; Porter, FD; Rao, R; Sidhu, R; Silber, SA; Soldatos, A; Solomon, B; Thurm, A; Vite, CH; Walkley, SU; Walters, KA; Weissfeld, L; Xu, X | 1 |
1 trial(s) available for 24-hydroxycholesterol and Orphan Diseases
Article | Year |
---|---|
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adolescent; Biomarkers; Calbindins; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Fatty Acid Binding Protein 3; Female; Hearing Loss, High-Frequency; Humans; Hydroxycholesterols; Injections, Spinal; Male; Niemann-Pick Disease, Type C; Rare Diseases; Young Adult | 2017 |